Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trial

Eli Lilly's weight-loss drug Zepbound demonstrated superior efficacy over Novo Nordisk's Wegovy in a head-to-head clinical trial involving 751 participants. Patients using Zepbound lost an average of 20.2% of their body weight after 72 weeks, compared to 13.7% weight loss for Wegovy users. Zepbound achieved a 47% greater relative weight loss than Wegovy, with over 31% of participants losing at least 25% of their body weight. These results were significant among adults who were obese or overweight with a related medical condition, excluding diabetes. The findings reinforce Zepbound's position as a more effective treatment for obesity, potentially influencing insurance coverage decisions. Eli Lilly plans to publish the results in a peer-reviewed journal and present them at a medical meeting next year.